Last checked at 
21 Mar 2018 15:15
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 28 February 2018
Net Assets | £227m |
Net Assets per share | 605p |
Share price | 586p |
Total value of unquoted investments | £22m |
Total number of portfolio companies | 95 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Array | 4.7 |
Biogen | 4.2 |
Celgene | 4.2 |
Neurocrine | 4.2 |
Regeneron | 3.7 |
Genmab | 3.7 |
Sage | 3.6 |
Vertex | 3.6 |
Gilead | 3.3 |
Exelixis | 3.2 |
----------- | |
Total | 38.4 |
Geographical Allocation | % NAV |
US & Canada | 89 |
Europe & UK | 11 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 91 |
Unquoted | 9 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 36 |
Mid Cap =USD1-10BN | 37 |
Small Cap | 27 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 38 |
Rare diseases | 15 |
CNS | 14 |
Inflammation | 6 |
Ophthalmology | 6 |
Metabolic | 5 |
Infectious Diseases | 4 |
Medtech | 4 |
Other | 8 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
21 MARCH 2018